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Objective. To assess the flare rate using published criteria (Disease Activity Score in 28 joints [DAS28-2] increase
between visits of >1.2 or >0.6 if current DAS28 ‡3.2) in patients receiving constant treatment, and to compare published
flare criteria to criteria used by study investigators after biologic treatment discontinuation in the ACT-RAY study.
Methods. Patients with rheumatoid arthritis (n5 553) were randomized to add tocilizumab to ongoing methotrexate,
or switch to tocilizumab plus placebo. If DAS28 £3.2 occurred at week 24, treatment remained constant until week
52; here we assessed the DAS28-2 flare rate. Between weeks 52 and 104, patients in sustained remission (DAS28 <2.6
at 2 consecutive visits 12 weeks apart) discontinued tocilizumab and were assessed every 4 weeks. Per protocol, flare
was defined as a worsening of disease activity that required treatment beyond the permitted therapy based on investi-
gator opinions (investigator flare) and was compared with the DAS28-2 definition.
Results. After tocilizumab discontinuation, DAS28-2 was sensitive (88–100%), but not specific (57–65%), for detecting
investigator flare. Under constant treatment, DAS28-2 criteria were met in 136 cases per 100 patient-years despite sta-
ble disease activity. Sustained flares were infrequent. Other DAS28-based criteria led to similar conclusions.
Conclusion. DAS28-based flare occurred more often than investigator-defined flares after biologic agent discontinua-
tion. More stringent criteria may be more appropriate for clinical practice.
Introduction
In rheumatoid arthritis (RA), the development of disease
flare criteria is an ongoing effort, serving relevant purposes
such as evaluating the duration of response after medication
withdrawal. In addition, the flare rate could be a standard out-
come measure for clinical research assessing stable treatment
conditions. In this context, Outcome Measures in Rheu-
matology (OMERACT) has launched an initiative aimed at
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defining flare (1). A preliminary investigation of 6 proposed
Disease Activity Score in 28 joints (DAS28)–based criteria
identified an increase in DAS28 .1.2 or .0.6, if DAS28
$3.2, as the most discriminating and valid criterion (2).
Two specific phases of the ACT-RAY study offer a unique
opportunity to investigate relevant aspects of flares: 1)
assessment of the flare rate (according to published criteria
[2]) between weeks 24 and 52, during which a large patient
subgroup received constant treatment (3,4), and 2) compari-
son (using sensitivity and specificity) of the flare criteria
implicitly used by the investigators with published criteria
(2) in the second year, during which patients reaching sus-
tained DAS28 remission discontinued tocilizumab (TCZ)
and subsequently other treatments, which were re-started
after investigators diagnosed a disease flare based on their
clinical judgment.
Patients and methods
Study design and procedures. ACT-RAY was a 3-year,
double-blind, placebo-controlled, parallel-group clinical
trial (NCT00810199) (3,4). Briefly, eligible patients had
active RA with DAS28 using the erythrocyte sedimentation
rate (ESR) of .4.4 at baseline, and received methotrexate
(MTX) for $12 weeks, with a stable dosage of $15 mg/
week. All patients received open-label TCZ 8 mg/kg intrave-
nously every 4 weeks, and were randomized to double-blind
treatment with MTX or placebo at a dose corresponding to
the pre-study period. Dose modifications of TCZ and MTX
were allowed only for safety reasons or in the context of the
treatment step-down (see below). Stable dosages of oral
corticosteroids (#10 mg/day prednisone equivalents) and
nonsteroidal antiinflammatory drugs were permitted.
After week 24, for patients who did not achieve low dis-
ease activity (LDA; DAS28-ESR .3.2), a treat-to-target
approach was used, including the addition of open-label
disease-modifying antirheumatic drugs (DMARDs). For
patients in LDA, treatment continued unchanged through
week 52, except for an optional steroid reduction not
below 5 mg/day of prednisone equivalents.
After week 52, the strategy included a treatment step-
down approach: patients who achieved sustained clinical
remission (DAS28-ESR ,2.6 at 2 consecutive visits 12
weeks apart) progressively discontinued study treatments:
first TCZ and subsequently, if still in sustained remission,
the open-label DMARD (where present) and the blinded
medication (MTX/placebo).
After treatment discontinuation, patients were moni-
tored for flares for 1 year. Flares were not defined by a par-
ticular disease activity level; a flare was considered a
worsening of the subject’s disease activity such that, in
the investigator’s opinion, it required treatment intensifi-
cation going beyond the permitted supportive therapy
(termed “investigator flare”). Flares could occur at or
between visits that were scheduled every 4 weeks, with
assessments including the components of DAS28 and the
American College of Rheumatology core data set.
Statistical analysis
In this post hoc analysis, all available observations from
the ACT-RAY intent-to-treat (ITT) population were used
to examine the occurrence of flares according to the sec-
ond criterion proposed by van der Maas et al (2): increase
in DAS28, between 2 visits, of .1.2 or .0.6 if the current
DAS28 $3.2 (termed “DAS28-2 flare”). Analyses were per-
formed for the other proposed flare criteria (see Supple-
mentary Table 1, available in the online version of this
article at http://onlinelibrary.wiley.com/doi/10.1002/acr.
22633/abstract). Event rates were reported as the count per
100 patient-years, with evaluable followup, and time-to-event
variables were assessed using the Kaplan-Meier method.
In patients under constant treatment between week 24 and
week 52, DAS28-2 flares were assessed with respect to the
previous assessment (reference visit), as well as sustained
(consecutive) flares 2 and 3 visits after a given reference visit,
up to week 44. The last observation carried forward method
was used to impute missing DAS28 values prior to valid
observations. For 28 patients (9%) who tapered oral cortico-
Significance & Innovations
 Objective disease flare criteria for rheumatoid
arthritis requires an understanding of how rheu-
matologists view the occurrence of flares and the
frequency of patients meeting flare criteria based
on disease activity when under constant treat-
ment. Using data from a large randomized study of
treat-to-target strategies based on tocilizumab
(TCZ) and methotrexate, this analysis 1) compared
published disease activity–based flare criteria
(Disease Activity Score in 28 joints [DAS28]-2:
increase in DAS28 between visits of .1.2 or .0.6
if current DAS28 $3.2) to criteria used by study
investigators after discontinuation of TCZ, and 2)
assessed the published criteria in a closely moni-
tored group of patients receiving constant TCZ-
based treatment according to the study protocol.
 DAS28-defined flares occurred more often than
flares identified by investigators after biologic agent
discontinuation. More stringent criteria may be
more appropriate for clinical practice.
 Under constant treatment, despite stable disease
activity and minimal efficacy related withdrawals,
DAS28-2–defined criteria were met quite often;
however, criteria were met mostly in relation to
disease activity fluctuations isolated to a single
visit. Clinical intervention may be more appropri-
ate after flare is observed at consecutive visits.
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steroids during this study phase, observations were censored
at the following visit.
In patients discontinuing TCZ in the second year,
DAS28-based flare was compared with investigator flare
(reference) in 2 types of analyses. First, patients with an
investigator flare were evaluated and assessed against the
proportion with DAS28-based flare at the same time. In a
second analysis, 5 time points were selected after TCZ dis-
continuation (immediately after TCZ discontinuation and
at 30, 60, 90, and 120 days thereafter) to evaluate the sensi-
tivity and specificity of flare detection over time, based on
DAS28-2, using investigator flare as a reference, with the
agreement between the 2 definitions based on Cohen’s
kappa.
Results
Patient disposition and background characteristics. The
ITT study population included 553 patients enrolled at 118
centers in 19 countries from Europe, America, and Asia. The
 
Figure 1. Overview of patient analysis set. ITT5 intent-to-treat; MTX5methotrexate; TCZ5
tocilizumab.
A B
Figure 2. Flares corresponded mostly to isolated disease activity peaks followed by return to previous levels. For patients
randomized to receive tocilizumab plus methotrexate (MTX) (A) or placebo (B), red dots indicate DAS28-2 flares (Disease
Activity Score in 28 joints between 2 visits.1.2, or.0.6 if the current DAS28$3.2). The analysis is based on the constant
treatment population (n5 313), i.e., patients with DAS28,3.2 (horizontal broken line) at week 24.
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patients’ mean6SD disease duration was 8.26 8.2 years and
their mean6SD baseline DAS28-ESR was 6.461.0. At week
24, 313 patients had achieved LDA. In the second year, 238
patients discontinued TCZ after reaching sustained remis-
sion and were assessed for flares in the study (Figure 1).
DAS28-2 flares under constant treatment. Disease activi-
ty between weeks 24 and 52 was stable (mean DAS28 of
2.24 and 2.21, respectively), and ,1% of patients withdrew
for efficacy reasons. Despite this, 136 DAS28-2 flares per 100
patient-years were recorded in 50% of patients (Kaplan-
Meier estimate) with a mean DAS28 of 3.7. Flares corre-
sponded mostly to isolated disease activity peaks, followed
by return to previous levels (Figure 2): the rate of sustained
flares $2, and 3 visits after a given reference visit (visit of
the first flare), up to week 44 was 52 and 25 per 100 patient-
years, concerning 17% and 8% of patients, respectively.
Over the same period, 36% of patients had $1 DAS28-2
flare. The flare incidence based on the other criteria varied
quite widely, but the reduction in rates for sustained flares
was similar to DAS28-2 (see Supplementary Table 2, avail-
able in the online version of this article at http://online
library.wiley.com/doi/10.1002/acr.22633/abstract).
Investigator flares versus DAS28-2 flares after TCZ
discontinuation. After discontinuation of one of the study
drugs according to the protocol, most patients experienced
an investigator flare (n5 200; Kaplan-Meier estimate 85%
[95% confidence interval (95% CI) 80%–89%]; median
time to flare: 87 days [95% CI 85–113 days]), with the
majority occurring following discontinuation of the first
drug (TCZ) (see Supplementary Figure 1, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.22633/abstract). Mean values
for disease activity measures at the time of TCZ discontinu-
ation and at flare, respectively, were as follows: DAS28-
ESR 1.6 and 4.4; tender joint count 1.9 and 9.1; swollen
joint count 0.64 and 4.6; Health Assessment Questionnaire
Disability Index 0.44 and 0.87; and patient global assess-
ment of disease activity (100-mm visual analog scale)
13.4 mm and 34.6 mm. Of the patients with an investigator
flare, 94% also had a DAS28-2 flare at the same visit. For
consecutive DAS28-2 flares including the previous visit and
at the 2 previous visits, the percentages were 52% and 35%,
respectively. Similar patterns were observed for the other
flare criteria (see Supplementary Table 1, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.22633/abstract).
DAS28-based flares were detected faster and more fre-
quently than investigator flares (median time: 56 versus 90
days). All patients with an investigator flare had a previous
or concomitant DAS28-2 flare. Comparison of the 2 defini-
tions at the 5 pre-specified time points (Table 1) demonstrat-
ed high sensitivity (88–100%), low specificity (57–68%),
and modest agreement (Cohen’s k,0.41). The prevalence of
investigator flare at each of these time points varied between
6.2% and 21.4%, with DAS28-2 flares between 45–53%, or
1.7–7.3 times higher. The positive predictive value was low
(14–42%) and the negative predictive value was high (96–
100%). Analyses based on the other criteria led to similar
conclusions (see Supplementary Table 3, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.22633/abstract).
Discussion
This study contributes to the discussion about defining
flares in RA, as we analyzed data from a treatment strategy
study with a 4-weekly visit schedule. This schedule is more
frequent than in most published studies, which rely on
assessments every 3 months. In a study phase characterized
by constant treatment, in stable disease activity and minimal
efficacy-related withdrawals, the DAS28-based flare criteria
from a published validation study (2) were met quite often;
however, they were mostly in relation to disease activity
fluctuations isolated to a single visit, potentially due to nor-
mal variability of clinical assessments. Recent modeling
work supports the existence of high random variability in
DAS28 over time (5). Therefore, utilizing a trend of DAS28
values over more than 1 visit, similar to the approach used
by many investigators in the present study, may be more
useful than single assessments in understanding disease
progression. Similar incidences of flare have been observed
Table 1. Investigator and DAS28-2 flares in the cross-sectional analyses following tocilizumab discontinuation in the second
year: values from 2 3 2 tables (DAS28 flare as a predictor of investigator flare) at the visit following the indicated number of











Prevalence of investigator flares 21.4 (45/210) 19.4 (33/170) 19.8 (26/131) 21.0 (21/100) 6.3 (5/80)
Prevalence of DAS28-2 flares 47.1 (99/210) 51.2 (87/170) 49.6 (65/131) 53.0 (53/100) 45.0 (36/80)
Sensitivity 93.3 (42/45) 87.9 (29/33) 100 (26/26) 90.5 (19/21) 100 (5/5)
Specificity 65.5 (108/165) 57.7 (79/137) 62.9 (66/105) 57.0 (45/79) 41.3 (44/75)
Positive predictive value 42.4 (42/99) 33.3 (29/87) 40.0 (26/65) 35.8 (19/53) 13.9 (5/36)
Negative predictive value 97.3 (108/111) 95.2 (79/83) 100 (66/66) 95.7 (45/47) 100 (44/44)
Kappa 0.41 0.28 0.4 0.30 0.15
P† , 0.0001 , 0.0001 , 0.0001 0.0001 0.0157
* Values are the percentage (no./total no.) unless indicated otherwise. DAS28-25Disease Activity Score in 28 joints between 2 visits .1.2 or .0.6
if the current DAS28 $3.2.
† By Fisher’s exact test.
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in patients receiving constant treatment of anti-tumor necro-
sis factor inhibitors (6).
After biologic agent discontinuation, investigator flares
were diagnosed at fairly high disease activity levels,
which was also the case for the patients’ assessments.
Investigator judgment used to identify flares was more
stringent than the DAS28-based definitions, as indicated
by a high sensitivity but rather low specificity. Under-
standing the correct time to respond to disease flares,
without overtreating, requires further study.
In this analysis, we only used clinical disease activity for
the assessment of flare; however, publications from the
OMERACT RA Flare Group (1,7) recently suggested includ-
ing the patients’ perspective (8) and expanding the set of
domains to, among others, fatigue, stiffness, and function.
Also, in the IMPROVED study, patients who were treated
for flares based on DAS28 criteria had similar efficacy out-
comes to those who were treated based on nonprotocol-
endorsed criteria, demonstrating that DAS28-based criteria
to detect flares that matter for outcomes are limited (9).
This study used physician assessments to define flare in
the context of a clinical trial, where the primary treatment
goal was drug-free remission. A limitation of this ap-
proach is the variability between physicians in their ass-
essments and opinions of when treatment is warranted.
Investigator judgment used to identify flares was more
restrictive than the best validated DAS28-based definition,
and solely basing treatment decision on these flare criteria
may lead to unnecessary interventions. Clinical interven-
tion may be more appropriate after flare is observed at con-
secutive visits. Indeed, the OMERACT RA Flare Group
also recognized that duration and intensity are both
important to define disease flares that impact physical
function and quality of life.
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